In This Article:
Amid recent market volatility, driven by concerns over new tariffs and economic data, investors are keenly observing stocks that may be undervalued in the current climate. Identifying stocks priced below their estimated fair value can offer potential opportunities for those looking to navigate these uncertain times effectively.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Semrush Holdings (NYSE:SEMR) | $9.57 | $19.02 | 49.7% |
| Berkshire Hills Bancorp (NYSE:BHLB) | $26.15 | $51.63 | 49.3% |
| Valley National Bancorp (NasdaqGS:VLY) | $8.78 | $17.25 | 49.1% |
| AGNC Investment (NasdaqGS:AGNC) | $9.52 | $18.57 | 48.7% |
| Hooker Furnishings (NasdaqGS:HOFT) | $10.45 | $20.67 | 49.4% |
| Advanced Micro Devices (NasdaqGS:AMD) | $103.22 | $204.09 | 49.4% |
| ZEEKR Intelligent Technology Holding (NYSE:ZK) | $24.26 | $48.51 | 50% |
| Haemonetics (NYSE:HAE) | $63.19 | $124.58 | 49.3% |
| Roku (NasdaqGS:ROKU) | $72.49 | $144.64 | 49.9% |
| Driven Brands Holdings (NasdaqGS:DRVN) | $17.86 | $35.09 | 49.1% |
Here's a peek at a few of the choices from the screener.
Driven Brands Holdings
Overview: Driven Brands Holdings Inc. operates as a provider of automotive services to retail and commercial customers across the United States, Canada, and internationally, with a market cap of approximately $2.93 billion.
Operations: Driven Brands Holdings Inc. generates revenue through its key segments: Car Wash ($587.24 million), Maintenance ($1.10 billion), Platform Services ($207.52 million), and Paint, Collision & Glass ($424.63 million).
Estimated Discount To Fair Value: 49.1%
Driven Brands Holdings appears undervalued based on its cash flows, trading at US$17.86, significantly below the estimated fair value of US$35.09. Despite a net loss of US$292.5 million in 2024, the company has reduced losses from the previous year and is forecast to achieve profitability within three years with earnings growth expected to outpace market averages. However, revenue growth projections at 4.8% annually are slower than broader market expectations of 8.3%.
BeiGene
Overview: BeiGene, Ltd. is an oncology company focused on discovering and developing cancer treatments across the United States, China, Europe, and internationally with a market cap of approximately $28.75 billion.
Operations: The company's revenue segment consists of Pharmaceutical Products, generating $3.81 billion.